Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aptevo Therapeutics ( (APVO) ) just unveiled an announcement.
In response to a compliance issue with Nasdaq Listing Rule 5550(b)(1), Aptevo Therapeutics Inc. successfully raised approximately $15.9 million in equity capital during the quarter ended June 30, 2025. The company conducted multiple equity offerings in April and June 2025, which they believe have brought their stockholders’ equity to at least $2.5 million, thus meeting the Nasdaq requirement. Aptevo is awaiting formal confirmation from Nasdaq regarding their compliance status.
The most recent analyst rating on (APVO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.
Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. operates in the biotechnology industry, focusing on the development of novel oncology and hematology therapeutics. The company is committed to advancing its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies to create innovative therapies for patients with cancer and other life-threatening diseases.
Average Trading Volume: 2,405,687
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.82M
See more data about APVO stock on TipRanks’ Stock Analysis page.